Clinical trials: Dual Antiplatelet Therapy
Coronary Artery Disease
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- NCT00528411
- Testing
- Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation
Cilostazol is an kind of oral antiplatelet agent with a rapid onset of action that selectively inhibits phosphodiesterase III, a mechanism different from adenosine diphosphate (ADP) receptor antagonists.
- Trial name
- NCT00404716
- Testing
- Cilostazol
- Sponsor
- Shenyang Northern Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
Patient Centered Machine Learning Model for Bleeding and Ischemic Risk
Dual antiplatelet therapy (DAPT) is indicated in all patients undergoing coronary stent implantation to prevent ischemic recurrencies despite an increased risk of bleeding.
- Trial name
- xDAPT (NCT06089304)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 19,000 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
Dual antiplatelet therapy with acetylsalicylic acid (ASA, aspirin) and clopidogrel is of great importance for treatment following coronary stenting.
- Trial name
- BOCLAplan (NCT01212302)
- Testing
- Optimizing ASA and clopidogrel treatment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Ruhr University of Bochum
Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
The purpose of this study is to determine whether 12-month prophylactic treatment with pantoprazole is superior to 1-month therapy without major cardiovascular events (MACE) increased significantly, in prevention of dual…
- Conditions
- Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract, Proton Pump Inhibitor
- Trial name
- DACAB-GI-2 (NCT03038009)
- Testing
- Pantoprazole
- Where
- China
- Sponsor
- Ruijin Hospital
Myocardial Infarction (MI)
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI).
- Trial name
- STREAMLINE (NCT07507500)
- Testing
- Prasugrel, Ticagrelor
- Where
- 5 sites in Ireland, Latvia and 3 more
- Volunteers
- 8,100 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Coronary Artery Disease
Short and Optimal Duration of Dual Antiplatelet Therapy Study
The purpose of this study is to evaluate safety of reduction of thienopyridine treatment period to 3 months after implantation of Cobalt-Chromium everolimus-eluting Stents.
- Trial name
- STOPDAPT (NCT01659034)
- Testing
- Thienopyridine for 3 months
- Where
- Japan
- Volunteers
- 1,525 people
- Sponsor
- Takeshi Morimoto
Coronary Stenoses
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month…
- Trial name
- TAILORED-CHIP (NCT03465644)
- Testing
- Tailored antithrombotic strategy, Conventional antithrombotic strategy
- Where
- 22 sites in South Korea
- Volunteers
- 2,018 people
- Sponsor
- Duk-Woo Park, MD
Dual Antiplatelet Therapy, Acute Coronary Syndrome
De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
High bleeding risk (HBR) patients, comprising up to 50% of those presenting with acute coronary syndrome (ACS), are a high-risk group that is increasing in size due to an aging population.
- Conditions
- Dual Antiplatelet Therapy, Acute Coronary Syndrome, Coronary Artery Disease
- Trial name
- DESC-HBR (NCT05903976)
- Testing
- P2Y12 inhibitor de-escalation
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Bleeding
Reversibility of Dual Antiplatelet Therapy by Platelets
The objective of the study is to test the hypothesis whether or not autologous stored platelets are able to offset the antiplatelet effect of aspirin and clopidogrel as assessed by state-of-the-art platelet function assays.
- Trial name
- NCT01248351
- Testing
- autologous stored platelets, administration of autologous stored platelets
- Where
- Austria
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Coronary Artery Disease, Coronary Thrombosis
Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)
Despite the benefit of drug-eluting stents (DES) to reduce the need for repeat revascularization procedures, concerns regarding late stent thrombosis (ST) have led to recent guidelines advocating extended prescription of dual…
- Trial name
- SEASIDE (NCT00963781)
- Testing
- Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Scripps Health
Coronary Artery Disease, Percutaneous Coronary Intervention
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
All patients undergoing elective or sub-acute PCI are screened by MULTIPLATE test for clopidogrel low-responsiveness after receiving 600 mg clopidogrel the day before. A cut off value has previously been established.
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes
- Trial name
- TAILOR (NCT01135667)
- Testing
- clopidogrel, Prasugrel 10 mg
- Where
- Denmark
- Volunteers
- 106 people
- Sponsor
- Lene Holmvang
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Atrial Fibrillation, Myocardial Infarction
Triple or Dual Antithrombotic Therapy After PCI (TRIDUAL-PCI) Coronary Intervention in Patients With Non-valvular Atrial Fibrillation. Real-world Italian Multicenter Registry (TRIDUAL-PCI)
Aim of this study is to describe clinical and procedural characteristics of real-world population initiated on triple antithrombotic therapy (double antiplatelet therapy+anticoagulant) or double antithrombotic therapy (single…
- Conditions
- Atrial Fibrillation, Myocardial Infarction, Anticoagulant-induced Bleeding, Coronary Disease
- Trial name
- TRIDUAL-PCI (NCT04291287)
- Testing
- Antithrombotic Agent
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Scientific Institute San Raffaele
Coronary Artery Disease, Stent Thrombosis
Optimal Duration of Dual Antiplatelet Therapy After Drug-eluting Stent Implantation
To compare treatment with aspirin alone versus the combined antiplatelet treatment aspirin and clopidogrel after 12 months of combined antiplatelet treatment following drug-eluting stent (DES) implantation.
- Conditions
- Coronary Artery Disease, Stent Thrombosis, Myocardial Ischemia
- Trial name
- OPTIDUAL (NCT00822536)
- Testing
- Aspirin and Clopidogrel, Aspirin
- Where
- France
- Volunteers
- 1,798 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cerebrovascular Disease
Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis
Multi-center, open-labelled randomized controlled trial, to study the effect of aspirin plus cilostazol and aspirin alone on the progression of intracranial arterial stenosis, in 200 chronic stroke patients with 50-99% stenosis…
- Trial name
- NCT00333164
- Testing
- Asprin, Cilostazol
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅱ (NCT07007143)
- Testing
- Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel
- Where
- China
- Volunteers
- 1,032 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Psoriasis (PsO), Psoriatic Arthritis (PsA)
A Clinical Trial of Antiplatelets in Psoriasis
The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more…
- Trial name
- NCT07744191
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Aneurysm Cerebral (Unruptured)
Dual Antiplatelet Therapy Adherence With Reminder App Usage
The purpose of this study is to evaluate Dual Antiplatelet Therapy adherence in patients undergoing stent-based endovascular treatment for unruptured cervical and intradural, intracranial aneurysms.
- Trial name
- NCT05071027
- Testing
- Endovascular Neurosurgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Montefiore Medical Center